Back Pain is an indication for drug development with over 50 pipeline drugs currently active. According to GlobalData, preregistered drugs for Back Pain have a 50% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Back Pain compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Likelihood of Approval Analysis for Back Pain

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Back Pain overview

Back pain, a prevalent discomfort, originates from various sources, including muscle strain, spinal issues, injury, or underlying conditions. It ranges from dull aches to sharp, debilitating pain, impacting mobility and daily activities. Common causes involve poor posture, muscle imbalances, herniated discs, or arthritis. Diagnosis incorporates physical exams, imaging, and medical history. Treatment involves pain management, rest, physical therapy, posture correction, and exercises to strengthen the back and core muscles. In severe cases or with persistent pain, medications, injections, or surgery may be considered. Managing back pain often requires a multifaceted approach tailored to the individual’s specific condition and needs.

For a complete picture of PTSR and LoA scores for drugs in Back Pain, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.